|Security||AKER / Akers Biosciences Inc. (00973E102)|
|Institutional Owners||22 (1 N-Q Owners)|
|Institutional Shares||9,332,992 - 11.39% (ex. N-Q)|
|Common Shares Outstanding||81,973,964 shares (as of 2017-12-31)|
|Institutional Value||$ 3,499,000 USD (ex. N-Q)|
Institutional Stock Ownership and Shareholders
Akers Biosciences Inc. (NASDAQ:AKER) has 22 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,332,992 shares.
Largest shareholders include
Vanguard Group Inc, Alpha Capital Anstalt, Empery Asset Management, LP, Courage Capital Management Llc, Citadel Advisors Llc, Geode Capital Management, Llc, Northern Trust Corp, Bard Associates Inc, IFP Advisors, Inc, and Bigger Capital Fund L P.
Akers Biosciences Inc. (NASDAQ:AKER) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/aker"><img src="https://images.fintel.io/us-aker-so.png" alt="AKER / Akers Biosciences Inc. Institutional Ownership"><a>
|HSBC HOLDINGS PLC||31,302||26,302||-15.97||4||22||450.00|
|BARD ASSOCIATES INC||139,600||121,700||-12.82||19||101||431.58|
|COURAGE CAPITAL MANAGEMENT LLC||1,032,000||360,428||-65.07||138||299||116.67|
|NORTHERN TRUST CORP||154,248||128|
|FIRST REPUBLIC INVESTMENT MANAGEMENT, INC.||0||10,000||0||8|
|Bank of New York Mellon Corp||79,843||0||-100.00||11||0||-100.00|
|IFP Advisors, Inc||83,876||111,876||33.38||11||93||745.45|
|BANK OF AMERICA CORP /DE/||421||379||-9.98||0||0|
|DEUTSCHE BANK AG\||243,600||0||-100.00||32||0||-100.00|
|ALPHA CAPITAL ANSTALT||2,516,635|
|TWO SIGMA SECURITIES, LLC||36,378||0||-100.00||5||0||-100.00|
|Advisor Group, Inc.||29,000||29,000||0.00||4||24||500.00|
|CITADEL ADVISORS LLC||30,508||322,650||957.59||55||267||385.45|
|VANGUARD GROUP INC||68,425||2,569,301||3,654.92||9||2,127||23,533.33|
|MILLENNIUM MANAGEMENT LLC||14,319||0||-100.00||12||0||-100.00|
|Hudson Bay Capital Management LP||563,075||50,326||-91.06||75||42||-44.00|
|GEODE CAPITAL MANAGEMENT, LLC||12,000||313,999||2,516.66||1||260||25,900.00|
|STATE STREET CORP||29,400||24|
|UBS Group AG||4,111||0||-100.00||1||0||-100.00|
|Ishares Trust (see advisory)|
|Renaissance Technologies LLC||243,600||0||-100.00||33||0||-100.00|
|Bigger Capital Fund L P||1,953,006||100,000||-94.88|
|PNC FINANCIAL SERVICES GROUP, INC.||230||230||0.00||0||0|
|SAN FRANCISCO SENTRY INVESTMENT GROUP (CA)||2,100||10,100||380.95||0||8|
|Virtu Financial LLC||254,338||0||-100.00||34||0||-100.00|
|ROYAL BANK OF CANADA||64,965||64,965||0.00||9||54||500.00|
|JANE STREET GROUP, LLC||34,452||29|
|Empery Asset Management, LP||724,200||2,491,591||244.05|
We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.
However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.
- We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( AKER / Akers Biosciences Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
- We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.
These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!
20h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
20h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Related News Stories
Today we will discuss Reata Pharmaceuticals (RETA), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. (63-13)
Good morning, and welcome to the Akers Biosciences Conference Call to discuss 2017 Earnings. As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Ben Simons with Akers Corporate Communications team. (3-14)
Flex Pharma (NASDAQ:FLKS) shares moved up sharply in early trading on Monday after the company announced positive top-line data from the phase 2 study of FLKS-787 in multiple sclerosis (NYSE:MS) patients with frequent muscle cramps/spasms and spasticity. (110-1)
as of ET
|Industry||In Vitro and In Vivo Diagnostic Substances|
LSE:AKR / AKERS BIOSCIENCES INC|